TVC Partners with Norbrook to Bring Felanorm™ to Independent Veterinary Practices
The Veterinary Cooperative (TVC), the premier group purchasing organization dedicated to supporting independent veterinary practices across the United States, is proud to announce a groundbreaking partnership with Norbrook Animal Health. This collaboration will bring to the forefront Felanorm™, Norbrook’s pioneering solution for managing hyperthyroidism in cats. This partnership represents a significant leap in the veterinary industry, combining the expertise of two key players to improve the lives of both veterinarians and their feline patients.
Hyperthyroidism in cats is a common and potentially debilitating condition that primarily affects older cats. This disorder is typically caused by an overproduction of thyroid hormones, leading to a variety of symptoms such as weight loss, increased appetite, vomiting, and hyperactivity. If left untreated, it can severely impact a cat’s quality of life and, in some cases, be life-threatening. Traditionally, hyperthyroidism has been managed through medication, surgery, or radioactive iodine therapy. However, these treatment options can be complex, costly, and difficult for some pet owners to manage, especially when it comes to medication administration. Felanorm™ stands out as a more accessible and practical solution.
Introducing Felanorm™: A Revolutionary Treatment for Feline Hyperthyroidism
Felanorm™ is a novel treatment designed to provide a more effective and convenient approach to managing feline hyperthyroidism. Unlike traditional oral medications that often come in tablet or capsule form—sometimes making it challenging to administer to cats—Felanorm™ is a honey-flavored liquid formula. This formulation not only appeals to the cat’s palate but also facilitates easier administration, ensuring greater compliance from both pet owners and veterinary professionals.
One of the standout features of Felanorm™ is its ability to provide accurate dose titration, an essential aspect of treating hyperthyroidism in cats. With the liquid format, veterinarians can adjust the dosage with precision, offering better control over the treatment plan. This flexibility helps ensure that each feline patient receives the appropriate amount of medication tailored to their specific needs, contributing to a more successful treatment outcome.
For the independent veterinary practices supported by TVC, the availability of Felanorm™ marks a pivotal moment in their ability to provide top-tier care for their feline patients. The collaboration with Norbrook Animal Health allows TVC members to access a treatment that is both innovative and effective, enhancing the overall quality of care delivered to cats suffering from hyperthyroidism.
The TVC-Norbrook Partnership: A Strategic Alliance for Enhanced Veterinary Care
The partnership between The Veterinary Cooperative (TVC) and Norbrook Animal Health is a natural fit, as both organizations are dedicated to improving the standards of care within the veterinary field. TVC, known for its extensive network of independent veterinary practices, continually strives to offer its members access to cutting-edge products and services that drive positive outcomes for their patients. With Felanorm™, TVC has once again ensured that its members have access to a high-quality, evidence-based solution that addresses a significant medical need in the veterinary community.
“We are thrilled to partner with Norbrook to bring Felanorm™ to our members,” said Kim London, Director of Strategic Partnerships at TVC. “Hyperthyroidism is a widespread condition that affects many cats, and Felanorm™ provides a trusted solution to help manage it effectively. This partnership continues our commitment to bringing high-quality, impactful products to the independent veterinary community.”
Through this collaboration, TVC members will have access to Felanorm™ at preferential pricing, enabling them to offer this advanced treatment to their clients while maintaining financial sustainability. This partnership not only benefits the veterinarians and their practices but ultimately improves the care provided to feline patients suffering from hyperthyroidism.
Norbrook’s commitment to innovation and the development of novel solutions aligns seamlessly with TVC’s mission to empower independent veterinarians. This joint effort underscores the shared vision of both organizations to make quality care more accessible to all pet owners, particularly in the treatment of complex conditions like hyperthyroidism.
“Norbrook and TVC have established a new partnership to enhance support for independent veterinarians with differentiated and novel solutions like Felanorm™,” said Brian Hopkins, Vice President of North America Sales and Marketing at Norbrook. “We’re excited to work alongside a group that shares our commitment to accessible innovation and better patient outcomes. This collaboration is a perfect example of how partnerships can drive meaningful change in the veterinary field.”
The Growing Need for Effective Hyperthyroidism Treatment
Hyperthyroidism in cats is a growing concern for veterinarians and pet owners alike. As feline populations age, the prevalence of this condition is expected to rise. Estimates suggest that hyperthyroidism affects approximately 1-2% of cats, with the majority of cases occurring in cats over the age of 10. As such, the need for effective, easy-to-administer treatments has never been more pressing.
Despite the availability of several treatment options, many cat owners struggle with the challenges of medication administration, particularly with oral tablets or capsules. Cats are often reluctant to take pills, and even the most well-intentioned pet owners can find it difficult to provide the correct dosage consistently. This can lead to suboptimal treatment outcomes, exacerbating the condition and prolonging the suffering of the cat.
Felanorm™ addresses these challenges head-on. Its liquid formulation not only simplifies administration but also improves the accuracy of dosing, allowing veterinarians to tailor the treatment to each cat’s unique needs. This makes it easier for pet owners to manage their cat’s condition at home, ensuring better adherence to the prescribed treatment plan.
Moreover, the honey-flavored solution is more palatable to cats, which helps eliminate the common problem of difficulty in getting a cat to ingest medication. The ease of use and improved patient compliance make Felanorm™ a game-changer in the management of feline hyperthyroidism.
Empowering Independent Veterinarians: A Win-Win for TVC Members
For TVC’s independent veterinary members, this partnership with Norbrook brings tangible benefits. In addition to offering an innovative and highly effective product, TVC’s collaboration with Norbrook provides access to ongoing support, education, and resources that will help veterinarians incorporate Felanorm™ into their practice.
Veterinarians who partner with TVC will gain access to comprehensive training on how to prescribe and monitor the use of Felanorm™ in their feline patients. This support is crucial in ensuring that veterinarians can confidently integrate the treatment into their existing protocols for managing hyperthyroidism, ultimately improving outcomes for cats and enhancing the overall client experience.
In addition, the preferential pricing offered through TVC’s purchasing power will enable independent practices to offer Felanorm™ at competitive rates, ensuring that high-quality care remains accessible to a broader range of pet owners. This is a key advantage for independent veterinary practices that may otherwise struggle to compete with larger corporate veterinary chains.
A Strong Partnership for Advancing Veterinary Care
As TVC and Norbrook Animal Health move forward with their partnership, the focus will remain on supporting independent veterinarians and ensuring the continued availability of innovative products like Felanorm™. By leveraging the strengths of both organizations, this collaboration has the potential to transform the landscape of veterinary care for cats with hyperthyroidism.
The TVC-Norbrook partnership is a shining example of how strategic alliances within the veterinary industry can drive positive change, improve patient care, and empower veterinary professionals. The introduction of Felanorm™ marks just the beginning of what promises to be a long and successful relationship between these two forward-thinking organizations.
As more independent veterinarians adopt Felanorm™ in their practices, the reach and impact of this partnership will continue to grow, benefiting countless cats and their owners. With this collaboration, TVC and Norbrook are ensuring that the future of feline hyperthyroidism treatment is both brighter and more accessible than ever before.
